Form 4: Precision BioSciences Director Melinda Brown Acquires Shares in Open Market Transaction

Director Melinda Brown of Precision BioSciences acquired 3,016 shares of common stock at an average price of $4.55 on December 26, 2024.

Summary

• Melinda Brown, a director at Precision BioSciences, purchased 3,016 shares of the company's common stock on December 26, 2024.
• The shares were acquired through multiple transactions at prices ranging from $4.54 to $4.55 per share, with a weighted average price of $4.55.
• Following the transaction, Ms. Brown directly owns 7,218 shares of Precision BioSciences common stock.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment, as it is a standard disclosure of an insider transaction. The purchase could be seen as a slightly positive signal, but it's not a major event.

Positives

• The director's purchase of shares could be seen as a positive signal of confidence in the company's future prospects.
• The transaction increases the director's alignment with shareholder interests.

Industry Context

This is a routine disclosure of an insider transaction, which is common in publicly traded companies. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The transaction is similar to other open market purchases by directors in comparable biotech companies.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the director's increased investment in the company.

Key Dates

Keywords

Precision BioSciences, Melinda Brown, insider trading, share purchase, director, DTIL, common stock